Read the criticism article -- the screeners were reviewed on all the external comparator trials and they are not for the "healthiest" naïve GBM patients possible like NWBO chose. Complete or near complete resection. So virtually NO naïve GBM patients should have been admitted to the trial according to the trial protocol NWBO posted on clinicaltrials.gov.
The "statistical consultants" made no such analysis -- read the criticism article. The NWBO statistical consultants" never had patient level data -- they only used aggregated data. Sorry, wrong.
Market Data 
Markets 
AI
